The market-implied odds of 96.5% against a hantavirus vaccine in 2026 reflect the absence of any candidate advancing beyond early preclinical or initial Phase 1 stages toward regulatory approval. Most development remains limited to animal models, including recent single-dose mRNA formulations that conferred full protection against Andes virus in hamsters, alongside ongoing DNA vaccine work and collaborations such as Moderna with Korean researchers. Hantavirus pulmonary syndrome remains rare, complicating large efficacy trials, and no licensed product exists outside limited inactivated options in parts of Asia for other strains. While a major outbreak or emergency funding could accelerate timelines, standard regulatory pathways for safety, immunogenicity, and field efficacy data make licensure by year-end highly improbable.